Your browser doesn't support javascript.
loading
Use of genomic and functional analysis to characterize patients with steroid-resistant nephrotic syndrome.
Kitzler, Thomas M; Kachurina, Nadezda; Bitzan, Martin M; Torban, Elena; Goodyer, Paul R.
Afiliación
  • Kitzler TM; Department of Medical Genetics, The Montreal Children's Hospital, McGill University Health Center, Montreal, Quebec, Canada.
  • Kachurina N; Department of Medicine, McGill University and McGill University Health Center, Montreal, Quebec, Canada.
  • Bitzan MM; Division of Nephrology, The Montreal Children's Hospital, McGill University Health Center, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec, H4A 3J1, Canada.
  • Torban E; Department of Medicine, McGill University and McGill University Health Center, Montreal, Quebec, Canada.
  • Goodyer PR; Division of Nephrology, The Montreal Children's Hospital, McGill University Health Center, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec, H4A 3J1, Canada. paul.goodyer@mcgill.ca.
Pediatr Nephrol ; 33(10): 1741-1750, 2018 10.
Article en En | MEDLINE | ID: mdl-29982877
ABSTRACT

BACKGROUND:

Children with genetic causes of steroid-resistant nephrotic syndrome (SRNS) usually do well after renal transplantation, while some with idiopathic SRNS show recurrence due to a putative podocyte-toxic factor. Distinguishing different forms of SRNS based on clinical criteria has been difficult. The aim of our study was to test a novel approach that allows categorization of patients into clinically useful subgroups.

METHODS:

Seventeen patients with clinically confirmed SRNS were analyzed by next-generation sequencing (NGS) of 37 known SRNS genes and a functional assay of cultured human podocytes, which indirectly tests for toxicity of patients' sera by evidenced loss of podocyte focal adhesion complex (FAC) number.

RESULTS:

We identified a pathogenic mutation in seven patients (41%). Sera from patients with monogenic SRNS caused mild loss of FAC number down to 73% compared to untreated controls, while sera from seven of the remaining ten patients with idiopathic SRNS caused significant FAC number loss to 43% (non-overlapping difference 30%, 95% CI 26-36%, P < 0.001). All patients with recurrent SRNS (n = 4) in the graft showed absence of podocyte gene mutations but significant FAC loss. Three patients had no mutation nor serum podocyte toxicity.

CONCLUSIONS:

Our approach allowed categorization of patients into three subgroups (1) patients with monogenic SRNS; (2) patients with idiopathic SRNS and marked serum podocyte toxicity; and (3) patients without identifiable genetic cause nor evidence of serum podocyte toxicity. Post-transplant SRNS recurrence risk appears to be low in groups 1 and 3, but high in group 2.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Medicamentos / Podocitos / Glucocorticoides / Síndrome Nefrótico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Resistencia a Medicamentos / Podocitos / Glucocorticoides / Síndrome Nefrótico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá